Aclaris Therapeutics: Promising Pipeline and Strategic Financial Management Justify Buy Rating
I'm PortAI, I can summarize articles.
Analyst Ram Selvaraju of H.C. Wainwright has reiterated a Buy rating on Aclaris Therapeutics, maintaining a price target of $16.00. This rating is supported by the company's promising pipeline, including the advancement of its anti-TSLP monoclonal antibody, bosakitug, into a Phase 2 trial for atopic dermatitis, and other key assets. Aclaris reported a net loss in Q3 2025 as expected but retains a strong cash position. Positive clinical results for ATI-2138 further bolster confidence in the company's growth prospects.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments